Vaccitech (NASDAQ:VACC) Shares Gap Down to $15.33

Vaccitech plc (NASDAQ:VACC)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $15.33, but opened at $14.53. Vaccitech shares last traded at $14.94, with a volume of 3,008 shares.

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Vaccitech in a research report on Wednesday, July 7th.

The company’s fifty day moving average is $15.16.

Vaccitech (NASDAQ:VACC) last issued its quarterly earnings results on Thursday, August 12th. The company reported ($0.64) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.10. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.15 million. As a group, research analysts predict that Vaccitech plc will post -1.51 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in VACC. Arena Capital Advisors LLC CA acquired a new position in Vaccitech during the 2nd quarter worth $515,000. Monashee Investment Management LLC acquired a new stake in shares of Vaccitech in the second quarter valued at $2,218,000. Morgan Stanley acquired a new stake in shares of Vaccitech in the second quarter valued at $284,000. Tudor Investment Corp Et Al acquired a new stake in shares of Vaccitech in the second quarter valued at $6,015,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Vaccitech in the second quarter valued at $194,000. Institutional investors own 8.52% of the company’s stock.

Vaccitech Company Profile (NASDAQ:VACC)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer.

Featured Story: What Are Treasury Bonds?

Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.